Current News:
Bioject Reports First Quarter 2009 Financial Results
Bioject Signs CRADA with US Navy to Study a Malaria Vaccine
Bioject Meets Milestone for Merial Limited
Bioject Announces FDA Market Clearance for the Zetajet™ Needle-Free Injection Therapy System
Fourth Quarter and Year-End 2008 Financial Results (Audio)
Bioject Reports December 31, 2008 Results
Bioject Enters into a Collaborative Research Agreement with IAVI for the Delivery of an HIV Vaccine Candidate
Bioject Extends Supply Agreement with Ferring Pharmaceuticals, Inc.
SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant
OTCBB: BJCT
ANNUAL REPORT